Abstract
Expression of the HER-2/neu proto-oncogene product was looked for immunohistochemically in 222 endometrial carcinomas in a retrospective followup study. The intensity of protein expression was correlated with patient survival. Median follow-up time was 4.8 years. In 109 (49%) of 222 endometrial carcinomas there was aberrant expression of HER-2/neu. HER-2/neu-expression did not correlate with p53-expression and proliferation rate, as determined immunohistochemically by the monoclonal antibody Ki-S1. In univariate statistical analysis aberrant HER-2/neu expression was not predictive of adjusted survival (p=0.18) and of disease-free survival (p=0.42). In multivariate analysis HER-2/neu-expression was not found to be an independent prognosticator (p=0.099) as compared to FIGO-stage (p=0.0001), histologic grade (p=0.00099) and proliferation rate (p=0.0013). Therefore immunohistochemically detected expression of HER-2/neu seems not to be a clinical prognosticator in endometrial cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Backe J, Gassel AM, Müller T, Schön S, Kaesemann H (1997) Tie Proliferationsrate als Prognosekriterium beim Endometriumkarzinom—eine immunhistochemische Analyse mit dem monoklonalen Antikörper Ki-S1. Zentralbl Gynakol (in press)
Berchuck A, Kamel A, Whitaker R (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087–4091
Berchuck A, Rodriguez G, Kinney RB (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15–21
Berchuck A (1995) Biomarkers in the endometrium. J Cell Biochem Suppl 23:174–178
Bigsby RM, Aixin L, Bomalaski J, Stehmann FB, Look KY, Sutton GP (1992) Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 79:95–100
Ferrara F, De Santis L, Mangili F et al. (1994) Role of DNA ploidy and erb-B2 oncogene expression in the prognosis of endometrial carcinoma. Path Res Pract 190:1039–1043
FIGO stagess (1989) 1988 revision. Gynecol Oncol 35:125–127
Grund C (1995) MEDAS, Statistikprogramm für Medizin und Biowissenschaften. Universität Würzburg
Hetzel DJ, Wilson TO, Kenney GL, Roche PC, Cha SS, Podratz KC (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47:179–185
Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW (1994) Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 53:84–92
Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G (1996) Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer-Letter 98:151–155
Kreipe HH, Alm P, Olsson H, Hauberg M, Fischer L, Parwaresch MR (1993) Prognostic significance of a formalinresistant nuclear proliferation antegen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 142:651–657
Lambkin HA, Mothersill CM, Kelehan P (1994) Variations in immunohistochemical detection of p53 protein overexpression. J Pathol 172:13–18
Lukes AS, Kohler MF, Pieper CF et al. (1994) Multivariable Analysis of DNA Ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73:2380–2385
Monk BJ, Chapman JA, Johnson GA, Brightman BK, Wilczinsky SP, Schell MJ, Fan H (1994) Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 171:1193–1198
Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY (1995) HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729–734
Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8:138–140
Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF (1995) Amplification and overexpression of HER-2/neu in endometrial cancers: correlation with overall survival. Cancer Res 55:5693–5698
Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS (1989) Endometrial cancer: Histologic correlates of immunohistochemical localization of progesterone and estrogen receptor. Obstet Gynecol 73:780–784
Slamon DJ, Godolphin W, Jones LA (1989) Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
Wang DP, Konishi I, Koshiyama M et al. (1993) Expression of c-erbB2-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer 72:2628–2637
World Health Organization (1994) Histologic Typing of Female Genital Tract Tumours. International Histological Classification of Tumours 13
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Backe, J., Gassel, A.M., Krebs, S. et al. Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet 259, 189–195 (1997). https://doi.org/10.1007/BF02505331
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02505331